Ofloxacin. A reappraisal of its use in the management of genitourinary tract infections

Drugs

Volumn 56, Issue 5, 1998, Pages 895-928

  Onrust, Susan V ^a   Lamb, Harriet M ^a   Barman Balfour, Julia A ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CEPHALOSPORIN DERIVATIVE; COTRIMOXAZOLE; OFLOXACIN;

ANTIBIOTIC SENSITIVITY; CHLAMYDIA TRACHOMATIS; CLINICAL TRIAL; DRUG BIOAVAILABILITY; ENTEROBACTERIACEAE; ENTEROCOCCUS; GASTROINTESTINAL DISEASE; GENITAL TRACT INFECTION; GONORRHEA; HAEMOPHILUS DUCREYI; HUMAN; META ANALYSIS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NEISSERIA GONORRHOEAE; NEUROTOXICITY; PELVIC INFLAMMATORY DISEASE; PHOTOSENSITIVITY; PSEUDOMONAS AERUGINOSA; REVIEW; SERRATIA MARCESCENS; SKIN MANIFESTATION; STAPHYLOCOCCUS SAPROPHYTICUS; TENDINITIS; UREAPLASMA UREALYTICUM; URINARY TRACT INFECTION;

CHLAMYDIA TRACHOMATIS; ENTEROBACTERIACEAE; ENTEROCOCCUS; HAEMOPHILUS DUCREYI; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NEISSERIA GONORRHOEAE; PSEUDOMONAS; PSEUDOMONAS AERUGINOSA; SERRATIA MARCESCENS; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS SAPROPHYTICUS; UREAPLASMA UREALYTICUM;

EID: 0031761295     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199856050-00015     Document Type: Review

References (212)

1. Todd PA, Faulds D. Ofloxacin: a reappraisal of its antimicrobial activity, pharmacology and therapeutic use. Drugs 1991 Nov; 42: 825-76
2. Monk JP, Campoli-Richards DM. Ofloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs 1987; 33: 346-90
3. Centers for Disease Control and Prevention. 1998 guidelines for treatment of sexually transmitted diseases. MMWR 1998 Jan 23; 47: 1-116
4. Petersen EE, de Isele TS, Pelz K, et al. Application of ofloxacin in gynaecology. Drugs 1987; 34 Suppl 1: 183-6
5. Motley M, Sarafian SK, Knapp JS, et al. Correlation between in vitro antimicrobial susceptibilities and β-lactamase plasmid contents of isolates of Haemophilus ducreyi from the United States. Antimicrob Agents Chemother 1992 Aug; 36 (8): 1639-43
6. National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing. Vol. 17. Villanova, PA: NCCLS, 1997. M100-S7
7. Choi K-H, Hong J-S, Kim S-K, et al. In vitro and in vivo activities of DW-116, a new fluoroquinolone. J Antimicrob Chemother 1997 Apr; 39: 509-14
8. Fukuoka Y, Ikeda Y, Yamashiro Y, et al. In vitro and in vivo antibacterial activities of T-3761, a new quinolone derivative, Antimicrob Agents Chemother 1993 Mar; 37: 384-92
9. Goto S, Sakuma Y, Miyazaki S, et al. In vitro and in vivo antibacterial activity of temafloxacin, a new quinolone [in Japanese]. Chemotherapy Tokyo 1993 Dec; 41 Suppl. 5: 25-42
10. Hayashi T, Watanabe T, Takenaka T, et al. Basic and clinical studies on SY5555 in the urological field [in Japanese]. Chemotherapy Tokyo 1994 Apr; 42 Suppl. 1: 475-84
11. Imada T, Goto S, Miyazaki S, et al. In vitro and in vivo antimicrobial effects of a new quinolone antimicrobial drug, grepafloxacin [in Japanese]. Jpn J Chemother 1995 Jul; 43 Suppl. 1: 29-41
12. Iwasaki H, Miyazaki S, Tsuji A, et al. In vitro and in vivo antibacterial activities of Q-35, a novel fluoroquinolone. Chemotherapy Basel 1995 Mar-Apr; 41: 100-12
13. Kim JH, Choi KH, Kim JW, et al. In vitro and in vivo antibacterial activity of CFC-222, a new fluoroquinolone. J Antimicrob Chemother 1998 Feb; 41: 223-9
14. Kim JH, Kang JA, Kim YG, et al. In vitro and in vivo antibacterial efficacies of CFC-222, a new fluoroquinolone. Antimicrob Agents Chemother 1997 Oct; 41: 2209-13
15. Nishino T, Tomii Y, Shibata K, et al. In vitro and in vivo antibacterial activity of NM441 [in Japanese]. Jpn J Chemother 1996 Mar; 44 Suppl. 1: 56-69
16. Nishino T, Shibata K, Kawai M, et al. In vitro and in vivo antibacterial activity of temafloxacin [in Japanese]. Chemotherapy Tokyo 1993 Dec: 41 Suppl. 5: 50-66
17. Nishino T, Yoneda H, Inoue R, et al. In vitro and in vivo antibacterial activities of grepafloxacin, a new synthetic antimicrobial agent [in Japanese]. Jpn J Chemother 1995 Jul; 43 Suppl. 1: 50-69
18. Siefert H. In vitro activity of trovafloxacin compared to ciprofloxacin, ofloxacin, fleroxacin and broad spectrum beta lactams against aerobe blood culture isolates [abstract no. T126]. Antiinfect Drugs Chemother 1998; 16 Suppl. 1: 67
19. Yamaguchi K, Domon H, Miyazaki S, et al. In vitro and in vivo antibacterial activities of CS-834, a new oral carbapenem. Antimicrob Agents Chemother 1998 Mar; 42: 555-63
20. Joly-Guillou ML, Judlin P, Lefevre JC, et al. Bacteria isolated in 1994-1995 from women with upper genital tract infections and men with urethritis: distribution and antimicrobial susceptibility [in French]. Presse Med 1996 Mar 2-9; 25: 342-8
21. Park KH, Cho IH, Lee JM, et al. In vitro and in vivo antibacterial activities of CFC-222, a novel broad spectrum fluoroquinolone. Drugs 1995; 49 Suppl. 2: 240-2
22. Dowzicky M, Nadler H, Dorr MB, et al. In vitro activity and pathogen responses of sparfloxacin (SPAR) vs comparative therapy for the treatment of respiratory tract, urinary tract (UTI) and skin and skin structure (SSSI) infections in North American Clinical trials [abstract]. 36th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1996 Sep 15: 281
23. Amyes SG, Baird DR, Crook DW, et al. A multicentre study of the in vitro activity of cefotaxime, cefuroxime, ceftazidime, ofloxacin and ciprofloxacin against blood and urinary pathogens. J Antimicrob Chemother 1994 Nov; 34: 639-48
24. Sugano T, Miyazaki S, Tsuji A, et al. Antibacterial activity of a new quinolone NM441 in vitro and in vivo [in Japanese]. Jpn J Chemother 1996 Mar; 44 Suppl. 1: 26-41
25. Tomii Y, Matsuda M, Sumimura N, et al. In vitro and in vivo antibacterial activities of a new quinolone, NM441 [in Japanese]. Jpn J Chemother 1996 Mar; 44 Suppl. 1: 74-89
26. Prosser BLT, Beskid G. Multicenter in vitro comparative study of fluoroquinolones against 25,129 Gram-positive and Gram-negative clinical isolates. Diagn Microbiol Infect Dis 1995; 21: 33-45
27. Kato N, Kato H, Tanaka-Bandoh K. Comparative in vitro and in vivo activity of AM-1155 against anaerobic bacteria. J Antimicrob Chemother 1997 Nov; 40: 631-7
28. Wolfson JS, Hooper DC. Fluoroquinolone antimicrobial agents. Clin Microbiol Rev 1989; 2 (4): 378-424
29. Rice RJ, Bhullar V, Mitchell SH, et al. Susceptibilities of Chlamydia trachomatis isolates causing uncomplicated female genital tract infections and pelvic inflammatory disease. Antimicrob Agents Chemother 1995 Mar; 39: 760-2
30. Huczko E, Kolkek B, Washo T, et al. In vitro activity of gatifloxacin against anaerobes, Mycoplasma, Ureaplasma, and Chlamydia spp [abstract no E-182]. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy: 1998 Sep 24-27; San Diego (CA): 222
31. Roblin PM, Hammerschlag MR. In vitro activity of a new quinolone, gatifloxacin, against Chlamydia pneumoniae and Chlamydia trachomatis [abstract no. E-195]. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy: 1998 Sep 24-27; San Diego (CA): 225
32. Soejima R, Niki Y, Kishomoto T, et al. Antichlamydial activities of newly developed fluoroquinolones and their potential future role in the treatment of chlamydial respiratory infections. Drugs 1991; 49 Suppl. 2: 257-9
33. Niki Y, Miyashita N, Kubota Y, et al. In vitro and in vivo antichlamydial activities of HSR-903, a new fluoroquinolone antibiotic. Antimicrob Agents Chemother 1997 Apr; 41: 857-9
34. Knapp JS, Back AF, Babst AF, et al. In vitro susceptibilities of isolates of Haemophilus ducreyi from Thailand and the United States to currently recommended and newer agents for treatment of chancroid. Antimicrob Agents Chemother 1993 Jul; 37: 1552-5
35. Puapermpoonsiri S, Watanahe K, Kato N, et al. In vitro activities of 10 antimicrobial agents against bacterial vaginosis-associated anaerobic isolates from pregnant Japanese and Thai women. Antimicrob Agents Chemother 1997 Oct; 41: 2297-9
36. Körner RJ, McMullin CM, Bowker KA, et al. The serum concentrations of desmethyl ofloxacin and ofloxacin N-oxide in seriously ill patients and their possible contributions to the antibacterial activity of ofloxacin. J Antimicrob Chemother 1994 Aug; 34: 300-3
37. Neu HC. Optimal characteristics of agents to treat uncomplicated urinary tract infections. Infection 1992; 20 Suppl. 4: S266-71
38. Naber KG, Hollauer K, Kirchbauer D, et al. In vitro activity of enoxacin versus ciprofloxacin, norfloxacin, ofloxacin, pefloxacin, gentamicin, augmentin, and cotrimoxazole against uropathogens from complicated urinary tract infection: a multicentre study [abstract no. T170]. Antiinfect Drugs Chemother 1998; 16 Suppl. 1: 78
39. Naber KG, Well M, Hollauer K, et al. In vitro activity of enoxacin versus ciprofloxacin, fleroxacin, lomefloxacin, ofloxacin, pefloxacin, and rufloxacin against uropathogens. Chemotherapy Basel 1998 Mar-Apr; 44: 77-84
40. Jones RN, Kehrberg EN, Erwin ME, et al. Prevalence of important pathogens and antimicrobial activity of parenteral drugs at numerous medical centers in the United States. I. Study on the threat of emerging resistances: real or perceived? Diagn Microbiol Infect Dis 1994; 19: 203-15
41. Jones RN, Reller LB, Rosati LA, et al. Ofloxacin, a new broad-spectrum fluoroquinolone: results from a multicenter, national comparative activity surveillance study. Diagn Microbiol Infect Dis 1992 Jul; 15: 425-34
42. Knapp JS, Washington JA, Doyle LJ, et al. Persistence of Neisseria gonorrhoeae strains with decreased susceptibilities to ciprofloxacin and ofloxacin in Cleveland, Ohio, from 1992 through 1993. Antimicrob Agents Chemother 1994 Sep; 38: 2194-6
43. Ridgway GL. Advances in the antimicrobial therapy of chlamydial genital infections. J Infect 1992; 25 Suppl. 1:51-9
44. Zhanel GG, Harding GKM, Guay DRP. Asymptomatic bacteriuria: which patients should be treated? Arch Intern Med 1990 July; 150: 1389-96
45. Jones RB, Van der Pol B, Johnson RB. Susceptibility of Chlamydia trachomatis to trovafloxacin. J Antimicrob Chemother 1997; 39 Suppl. B: 63-5
46. Naber KG, Thyroff-Friesinger U. Spectrum and susceptibility of pathogens causing acute uncomplicated lower UTI in females and its correlation to bacteriologic outcome after single dose therapy with fostomycin trometamol versus ofloxacin/co-trimoxazole. Infection 1992; 20 Suppl. 4: S296-301
47. Naber KG, Hollauer K, Kirchbauer D, et al. In vivo activity of gatifloxacin versus trovafloxacin, moxifloxacin, ciprolloxacin. fleroxacin, and ofloxacin against uropathogens [abstract no. T136]. Antiinfect Drugs Chemother 1998; 16 Suppl. 1: 69
48. Martínez L, Pascual A, Tran J, et al. Plasmid-mediated resistance to quinolones [abstract]. Proceedings of the 37th International Conference on Antimicrobial Agents and Chemotherapy. Program Addendum 1997 Sep 1-Oct 28: LB-20
49. Thomson KS, Sanders WE, Sanders CC. USA resistance patterns among UTI pathogens. J Antimicrob Chemother 1994; 33 Suppl. A: 9-15
50. Acar JF, Goldstein FW. Trends in bacterial resistance to fluoroquinolones. Clin Infect Dis 1997; 24 Suppl. 1: S67-S73
51. Jones RN. Fluoroquinolone (lomefloxacin) international surveillance trial: a report of 30 months of monitoring in vitro activity. Am J Med 1992 Apr 6; 92 Suppl. 4A: 52S-57S
52. Comegna M, Guzmán M, Merentes A, et al. Comparative in vitro activity of fluoroquinolones (FLQ) against usual pathogens [abstract no. 12,004]. Proceedings of the 8th International Congress on Infectious Diseases 1998 May 15-18; 14, Boston (MA)
53. Aguiar JM, Chacon J, Canton R, et al. The emergence of highly fluoroquinolone-resistant Escherichia coli in community-acquired urinary tract infections. J Antimicrob Chemother 1992 Mar; 29: 349-50
54. Ozeki S, Deguchi T, Yasuda M, et al. Development of a rapid assay for detecting gyrA mutations in Escherichia coli and determination of incidence of gyrA mutations in clinical strains isolated from patients with complicated urinary tract infections. J Clin Microbiol 1997 Sep; 35: 2315-9
55. Kumamoto Y, Tsukamoto T, Hirose T, et al. Comparative studies on activities of antimicrobial agents against causative organisms isolated from patients with urinary tract infections (1996). III. Secular changes in susceptibility [in Japanese]. Jpn J Antibiol 1998 Mar; 51: 143-236
56. Pérez-Trallero E, Urbieta M, Jimenez D, et al. Ten-year survey of quinolone resistance in Escherichia coli causing urinary tract infections. Eur J Clin Microbiol Infect Dis 1993; 12: 349-51
57. Threlfall EJ, Cheasty T, Graham A, et al. High-level resistance to ciprofloxacin in Escherichia coli. Lancet 1997 Feb 8; 349: 403-4
58. Stein GE, Schooley S, Mcmillan J. Urinary pharmacodynamics of low-dose ciprofloxacin and ofloxacin. Diagn Microbiol Infect Dis 1998 Apr; 30: 261-5
59. Wolfson JS, Hooper DC. Comparative pharmacokinetics of ofloxacin and ciprofloxacin. Am J Med 1989 Dec 29; 87 Suppl C: 31S-36S
60. Israel D, Gillum JG, Turik M, et al. Pharmacokinetics and serum bactericidal titers of ciprofloxacin and ofloxacin following multiple oral doses in healthy volunteers. Antimicrob Agents Chemother 1993 Oct; 37: 2193-9
61. Echols R, Weinstein MP, O'Keeffe B, et al. Comparative crossover assessment of serum bactericidal activity and pharmacokinetics of ciprofloxacin and ofloxacin. J Antimicrob Chemother 1994 Jan; 33: 111-8
62. Zeiler H-J, Beermann D, Wingender W, et al. Bactericidal activity of ciprofloxacin, norfloxacin and ofloxacin in serum and urine after oral administration to healthy volunteers. Infection 1988; 16 Suppl. 1: S19-23
63. Edlund C, Sjösledt S, Nord CE. Comparative effects of levofloxacin and ofloxacin on the normal oral and intestinal microflora. Scand J Infect Dis, 1997: 383-6
64. Nord CE. Effect of quincilones on the human intestinal microflora. Drugs 1995; 49 Suppl. 2: 81-5
65. Anonymous. Ofloxacin. In: McEvoy G, editor. AHFS Drug Information. Bethesda (MD): American Society of Health System Pharmacists, 1998
66. Mueller BA, Brierton DG. Abel SR et al. Effect of enteral feeding with Ensure on oral bioavailabilities of ofloxacin and ciprofloxacin. Antimicrob Agents Chemother 1994 Sep; 38: 2101-5
67. Taira K, Koga H, Kohno S. Accumulation of a newly developed fluoroquinolone, OPC-17116, by human polymorphonuclear leukocytes. Antimicrob Agents Chemother 1993 Sep; 37 (9): 1877-81
68. Pascual A, García I, Conejo MC, et al. Fluorometric and high-performance liquid chromatographic measurement of quinolone uptake by human neutrophils. Eur J Clin Microbiol Infect Dis 1991 Nov; 10: 969-71
69. Perea EJ, Garcia I, Pascual A. Comparative penetration of lomefloxacin and other quinolones into human phagocytes. Am J Med 1992 Apr 6; 92 Suppl. 4A: 48S-51S
70. Yew WW, Wong CF, Wong PC, et al. Correlation of serum ofloxacin concentration and serum creatinine level in patients on prolonged therapy. Int J Clin Pharmacol Res 1993; 13 (5): 243-5
71. Martin C, Lambert D, Bruguerolle B, et al. Ofloxacin pharmacokinetics in mechanically ventilated patients. Antimicrob Agents Chemother 1991 Aug; 35: 1582-5
72. Flor SC, Rogge MC, Chow AT. Bioequivalence of oral and intravenous ofloxacin after multiple-dose administration to healthy male volunteers. Antimicrob Agents Chemother 1993 Jul; 37: 1468-72
73. Naber KG, Kinzig M, Sörgel F, et al. Penetration of ofloxacin into prostatic fluid, ejaculate and seminal fluid. Infection 1993 Mar-Apr; 21: 98-100
74. Ichihara N, Tachizawa H, Tsumura M, et al. Phase I study on DL-8280. Chemotherapy Tokyo 1984 Feb; 23 Suppl. 1: 118-49
75. Kawauchi A, Kamoi K, Ohne T, et al. Ofloxacin concentration in prostatic tissue [in Japanese]. Hinyokika Kiyo 1993 Dec; 39: 1191-3
76. Morita M, Hasuda A. Ofloxacin concentrations in human prostatic tissue after 3 days administration [in Japanese]. Hinyokika Kiyo 1989; 35: 187-90
77. Tallarigo C, Comunale L, Baldassare R, et al. Ofloxacin (Oflocin): evaluation of distribution in the prostate: clinical efficacy in bacterial prostatitis. Clin Trials J 1989; 26 (4): 233-7
78. Aagaard J, Knes J, Madsen PO. Prostatic tissue levels of ofloxacin. Urology 1991 Oct; 38: 380-2
79. Riedasch G, Möhring K, Brkovic D. Concentration of ofloxacin in prostatic tissue during TURP [abstract]. Drugs 1993; 45 Suppl. 3: 356
80. Naber KG, Adam D, Kees F. In vitro activity and concentrations in serum, prostatic secretion and adenoma tissue of ofloxacin in urological patients. Drugs 1987: 34 Suppl. 1: 44-50
81. Berger SA, Yavetz H, Paz G, et al. Concentration of ofloxacin and ciprofloxacin in human semen following a single oral dose. J Urol 1990 Sep: 144: 683-4
82. Cho N, Koh Y, Hara Y, et al. Fundamental and clinical evaluations of DL-8280 in obstetrical and gynecological field. Chemotherapy Tokyo 1984 Feb; 32 Suppl. 1: 908-24
83. Hayasaki M, Kohdoh H, Itoh K, et al. Fundamental and clinical studies of DL-8280 in obstetrical and gynecological field. Chemotherapy Tokyo 1984; 32 Suppl. 1: 934-43
84. Tartaglione TA, Johnson CR, Brust P, et al. Pharmacodynamic evaluation of ofloxacin and trimethoprim-sulfamethoxazole in vaginal fluid of women treated for acute cystitis. Antimicrob Agents Chemother 1988 Nov; 32 (11): 1640-3
85. Suzuki K, Adachi S, Matsuura T, et al. Ofloxacin in geriatric patients: efficacy of a single daily dose [in Japanese]. Chemotherapy Tokyo 1991 Nov; 39: 1052-64
86. Akerele JO, Okhamafe AO. Influence of oral co-administered metallic drugs on ofloxacin pharmacokinetics. J Antimicrob Chemother 1991 Jul; 28: 87-94
87. Leigh DA, Walsh B, Harris K, et al. Pharmacokinetics of ofloxacin and the effect on the faecal flora of healthy volunteers. J Antimicrob Chemother 1988: 22 Suppl. C: 115-25
88. Auhert J, Lefebvre MA, Couet W, et al. Diffusion of ofloxacin into the prostate and kidney. Rev Infect Dis 1988 Jan-Feb; 10 Suppl. 1: S170
89. Stamm WE, Hooton TM. Management of urinary tract infections in adults. N Engl J Med 1993 October 28: 329 (18): 1328-34
90. Rubin RH, Shapiro ED, Andriole VT. Evaluation of new anti-infective drugs for the treatment of urinary tract infection. Clin Infect Dis 1992; 15 Suppl 1: S216-27
91. Sobel JD, Kaye D. Urinary tract infections. In: Mandell GL, Bennett JE, Dolin R, editors. Principles and practice of infectious diseases. 4th ed. v. 1. New York: Churchill Livingstone, 1995: 662-90
92. Hall JC. Antimicrobial prophylaxis for patients undergoing transurethral resection of the prostate. Clin Drug Invest 1995; 9 Suppl 1: 20-4
93. Giamarellou H, Dontas AS, Zorhas P, et al. Asymptomatic bacteriuria in freely voiding elderly subjects: long-term continuous vs pulse treatment with ofloxacin. Clin Drug Invest 1998 Mar; 15: 187-95
94. Lutz FB. Single-dose efficacy of ofloxacin in uncomplicated gonorrhea. Am J Med 1989; 87 Suppl. 6C: 69S-74S
95. Schalkhäuser K. Comparison of iv ofloxacin and piperacillin in the treatment of complicated urinary tract infections. J Antimicrob Chemother 1990 Nov; 26 Suppl. D: 93-7
96. Spencer RC, Cole TP. Ofloxacin versus trimethoprim and cotrimoxazole in the treatment of uncomplicated urinary tract infection in general practice. Br J Clin Pract 1992; 46 (1): 30-3
97. Hooton TM, Johnson C, Winter C, et al. Single-dose and three-day regimens of ofloxacin versus trimethoprim-sulfamethoxazole for acute cystitis in women. Antimicrob Agents Chemother 1991 Jul; 35: 1479-83
98. Cox CE, Serfer HS, Mena HR, et al. Ofloxacin versus trimethoprim/sulfamethoxazole in the treatment of uncomplicated urinary tract infection. Clin Ther 1992 May-Jun; 14: 446-57
99. Raz R, Rozenfeld S. 3-Day course of ofloxacin versus cefalexin in the treatment of urinary tract infections in postmenopausal women. Antimicrob Agents Chemother 1996 Sep; 40: 2200-1
100. Naber KG, Koch EMW. Cefuroxime axetil versus ofloxacin for short-term therapy of acute uncomplicated lower urinary tract infections in women. Infection 1993 Jan-Feb; 21: 34-9
101. Raz R, Rottensterich E, Leshem Y et al. Double-blind study comparing 3-day regimens of cefixime and ofloxacin in treatment of uncomplicated urinary tract infections in women. Antimicrob Agents Chemother 1994 May; 38: 1176-7
102. Cox CE. Ofloxacin in the management of complicated urinary tract infections, including prostatitis. Am J Med 1989 Dec 29; 87 Suppl. 6C: 61S-68S
103. Mattina R, Cocuzza CE, Cesana M et al. Rufloxacin once daily versus ofloxacin twice daily for treatment of complicated cystitis and upper urinary tract infections. Infection 1993 Mar-Apr; 21: 106-11
104. Kawada Y, Okada K, Kumamoto Y, et al. Comparative study on fleroxacin and ofloxacin in complicated urinary tract infections [in Japanese]. Chemotherapy Tokyo 1990 Nov; 38 Suppl. 2: 571-90
105. Kumazawa J, Matsumoto T, Kamidono S, et al. A double-blind comparative study of temafloxacin with ofloxacin in complicated urinary tract infections [in Japanese]. Chemotherapy Tokyo 1993 Dec: 41 Suppl. 5: 593-608
106. Kumazawa J, Matsumoto T, Kamidono S, et al. Dose-finding study on temafloxacin in complicated urinary tract infections [in Japanese]. Chemotherapy Tokyo 1993 Dec; 41 Suppl. 5: 578-92
107. Kawada Y, Kumamoto Y, Aso Y, et al. Comparative study on levofloxacin and ofloxacin in complicated urinary tract infections [in Japanese]. Chemotherapy Tokyo 1992 May; 40 Suppl. 3: 230-47
108. McCarty J, Heyd A, Echols RM, et al. Prospective, randomized, double-blind comparison of 100 mg ciprofloxacin (CIP) twice daily for 3 days, trimethoprim/sulfamethoxazole (TS) 160/800 mg twice daily for 3 days and ofloxacin (OFL) 200 mg twice daily for 3 days in the treatment of patients with acute uncomplicated lower UTI [abstract]. 5th International Symposium on New Quinolones: 1994 Aug 25-7; Singapore, 136
109. Henry D, Sparfloxacin Multicenter Study Group. Treatment of community-acquired acute uncomplicated urinary tract infections with sparfloxacin and ofloxacin [abstract]. 36th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1996 Sep 15, 281
110. Iravani A. A multicenter comparison of the safety and efficacy of 3 days of lomefloxacin vs 3 days of ofloxacin in the treatment of women with uncomplicated urinary tract infection [abstract]. 9th Mediterranean Congress of Chemotherapy 1994 Jun 12-17 Milan, 67
111. Richard G, Deabate C, Ruoff, G, et al. Short-course levofloxacin (250mg QD) vs ofloxacin (200mg BID) in uncomplicated ITI: a double-blind randomized trial [abstract no. L-81]. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy: 1998 Sep 24-27; San Diego, CA, 572
112. Naber KG, Thyroff-Friesinger U. Fosfomycin trometamol versus ofloxacin/co-trimoxazole as single dose therapy of acute uncomplicated urinary trad infection in females: a multicentre study. Infection 1990; 18 Suppl. 2: S70-6
113. Guibert J, Botto H, Douetteau C. Comparative study of a single dose of ofloxacin 400mg or pefloxacin in 800mg in the treatment of uncomplicated acute cystitis in women under 65 [abstract]. Can J Infect Dis 1995 Jul; 6 Suppl. C: 415C
114. Pfau A, Sacks TG. Single dose quinolone treatment in acute uncomplicated urinary tract infection in women. J Urol 1993 Mar; 149: 532-4
115. Kumamoto Y. Single-dose treatment of female acute uncomplicated cystitis. Infection 1992; 20 Suppl. 3: S173-4
116. Wood CA, Abrutyn E. Optimal treatment of urinary tract infections in elderly patients. Drugs Aging 1996 Nov; 9 (5): 352-62
117. Nygaard IE, Johnson JM. Urinary tract infections in elderly women. Am Fam Physician 1996 Jan; 53 (1): 175-82
118. Plumridge RJ, Golledge CL. Treatment of urinary tract infection: clinical and economic considerations. Pharmacoeconomics 1996 Apr; 9: 295-306
119. Zorbas P, Giamarellou H, Staszewska-Pistoni M, et al. Comparison of 2 oral ofloxacin regimens for the treatment of bacteriuria in elderly subjects. Drugs 1995; 49 Suppl. 2: 384-6
120. Giamarellou H, Iakovou M, Pistoni M, et al. Kinetics and comparative efficacy of ofloxacin versus co-trimoxazole in the asymptomatic bacteriuria of elderly subjects. Chemotherapy Basel 1991; 37 Suppl. 1: 19-24
121. Cox CE. Parenteral ofloxacin in treatment of pyelonephritis. Urology 1991 Mar; 37 Suppl.: 16-20. Summary in 2 parts (Pt A)
122. Kumazawa J, Matsumoto T, Kumamoto Y, et al. Clinical dose finding study on NM441 in complicated urinary tract infections [in Japanese]. Jpn J Chemother 1996 Mar; 44 Suppl. 1: 451-61
123. Raz R, Naber KG, Raizenberg C. Ciprofloxacin 250mg b.i.d. vs ofloxacin 200mg b.i.d. in the treatment of complicated U.T.I. in women, an Israel-Germany study. [abstract no. 59,006] 8th International Congress on Infectious Diseases: 1998 May 15-18; Boston (MA)
124. Naber KG, Bischoff W, Huber K. Open, randomised, multicentre study with cefuroxime axetil (CFX) versus ofloxacin (OFX) in women with uncomplicated pyelonephritis. [abstract no. M238] 2nd European Congress of Chemotherapy and 7th Biennial Conference on Antiinfective Agents and Chemotherapy: 1998 May 10-10-13; Hamburg, 16:35
125. Peters H-J. Sequential therapy with ofloxacin in complicated urinary tract infections: a randomized comparative study with ciprofloxacin. Infection 1992 May-Jun; 20: 172-3
126. Uchibayashi T, Nishino A, Hisazumi H, et al. Clinical evaluation of ofloxacin in the treatment of chronic complicated urinary tract infection. Hinyokika Kiyo 1990; 36: 725-30
127. Veyssier P, Martin F, Gallinari C, et al. Clinical evaluation of ofloxacin at a daily dosage adapted to creatinine clearance in elderly subjects [abstract]. Drugs 1993; 45 Suppl. 3: 265
128. McCue JD, Gaziano P, Orders D. A randomised controlled trial of ofloxacin 200mg 4 times daily or twice daily vs ciprofloxacin 500mg twice daily in elderly nursing home patients with complicated UTI. Drugs 1995; 49 Suppl. 2: 368-73
129. Ishioka T. Comparative evaluation of panipenem/betamipron and ofloxacin on urinary tract infection in the elderly [abstract]. First European Congress of Chemotherapy 1996 May 14, Glasgow, W128
130. Martínez-Piédrola E, Pérez de Oteyza C, Martinez-Pérez E, et al. Complicated urinary tract infections in the elderly: clinical and bacteriological efficacy of ofloxacin vs amoxicillin-clavulanate [abstract]. Can J Infect Dis 1995 Jul; 6 Suppl. C: 416C
131. Bassetti D, Concia E, Solbiati M, et al. Ffficacy of ofloxacin in nosocomial urinary tract infections: an open study [abstract]. Eur J Clin Microbiol Infect Dis 1991 Spec. issue: 319
132. Scully BE, Clynes N, Neu HC. Oral ofloxacin therapy of infections due to multiply-resistant bacteria. Diagn Microbiol Infect Dis 1991 Sep-Oct; 14: 435-41
133. Ramirez JA. Advances in antibiotic therapy: parenteral to oral switch. Clinician 1993; 11 (3): 38-40
134. Markham A, Brogden RN. Cefixime: a review of its therapeutic efficacy in lower respiratory tract infections. Drugs 1995; 49 (6): 1007-22
135. Cox CE. Gentry LO, Rodriguez-Gomez G. Multicenter open-label study of parenteral ofloxacin in treatment of pyclonephritis in adults. Urology 1992 May; 39: 453-6
136. Mouton Y, Leroy O, Beuscart C, et al. Efficacy of intravenous ofloxacin: a French multicentre trial in 185 patients. J Antimicrob Chemother 1990 Nov; 26 Suppl. D: 115-21
137. Bischoff W. Clinical experience with intravenous ofloxacin therapy in complicated urinary tract infections [abstract]. Eur J Clin Microbiol Infect Dis 1991 Spec. issue: 321-2
138. Presterl E, Boguar H, Winkler S, et al. Sequential intravenous/ oral ofloxacin in the treatment of urogenital infections [in German]. Wien Med Wochenschr 1992; 142 (17): 381-4
139. Regamey C, Steinbach-Lebbin C. Severe infections treated with intravenous ofloxacin: a prospective clinical multicentre Swiss study. J Antimicrob Chemother 1990 Nov; 26 Suppl. D: 107-14
140. Aagaard J, Madsen PO. Diagnostic and therapeutic problems in prostatitis: therapeutic position of ofloxacin. Drugs Aging 1992 May-Jun; 2: 196-207
141. Koff W. Clinical trial comparing lomefloxacin andofloxacin in the treatment of chronic bacterial prostatitis [in Portuguese]. Rev Bras Med 1996 Jan-Feb; 53: 88-91
142. Finkelstein LH, Arsht DB, Manfrey SJ, et al. Ceftriaxone in the prevention of postoperative infection in patients undergoing transurethral resection of the prostate. Am J Surg 1984 Oct 19 (Ceftriaxone Symposium): 19-21
143. Botto H, Butreau-Lemaire M, Levy S, et al. Oral ofloxacin versus intramuscular ceftriaxone in antibiotic prophylaxis in transurethral prostate resection [in French]. Prog Urol 1993 Aug-Sep; 3: 569-75
144. Madsen PO, Malek GH, Kahn JB. Single dose UTI prophylaxis in transurethral surgery. Oral ofloxacin vs parenteral cefotaxime. Drugs 1995; 49 Suppl. 2: 480-2
145. Morita M, Ito S, Suzuki K. Clinical evaluation of oral ofloxacin in 3-day therapy for transurethral resection of the prostate [in Japanese]. Hinyokika Kiyo 1992 Jul; 38: 869-74
146. Charuwichitratana S, Polnikorn N, Chitvarakorn A. Double-blind clinical trial of pefloxacin versus ofloxacin in the treatment of acute uncomplicated gonococcal urethritis in men. J Infect Dis Antimicrob Agents 1996 Jan-Apr; 13: 7-10
147. Covino JM, Cummings M, Smith B, et al. Comparison of ofloxacin and ceftriaxone in the treatment of uncomplicated gonorrhea caused by penicillinase-producing and non-penicillinase-producing strains. Antimicrob Agents Chemother 1990 Jan; 34 (1): 148-9
148. Black JR, Long JM, Zwickl BE, et al. Multicenter randomized study of single-dose ofloxacin versus amoxicillin-probenecid for treatment of uncomplicated gonococcal infection. Antimicrob Agents Chemother 1989 Feb; 33 (2): 167-70
149. Blomer R, Bruch K, Klose U. Ofloxacin in the treatment of gonococcal and chlamydial urethritis. Clin Ther 1988; 10(3): 263-5
150. Hooton TM, Batteiger BE, Judson FN, et al. Ofloxacin versus doxycycline for treatment of cervical infection with Chlamydia trachomatis. Antimicrob Agents Chemother 1992 May; 36: 1144-6
151. Judson FN, Beals BS, Tack KJ. Clinical experience with ofloxacin in sexually transmitted disease. Infection 1986; 14 Suppl. 4: S309-10
152. Martens MG. Double-blind prospective randomized evaluation of ofloxacin versus doxycycline in the treatment of non-gonococcal cervicitis. South Med J 1992 Sep; 85: 3S-51
153. Mogabgab WJ, Holmes B, Murray M, et al. Randomized comparison of ofloxacin and doxycycline for chlamydia and ureaplasma urethritis and cervicitis. Chemotherapy Basel 1990 Jan; 36: 70-6
154. Vilata JJ, Garcia de Lomas J, Sanchez J, et al. A double-blind randomized study comparing two ofloxacin regimens vs minocycline in the treatment of nongonococcal urethritis [abstract]. Rev Infect Dis 1989 Jul-Aug; 11 Suppl. 5: S1285-6
155. Ibsen HHW, Møller BR, Halkier-Sørensen L. Treatment of non-gonococcal urethritis: comparison of ofloxacin and erythromycin. Sex Transm Dis 1989 Jan-March; 16 (1): 32-5
156. Martens MG, Gordon S, Yarborough DR, et al. Multicenter randomized trial of ofloxacin versus cefoxitin and doxycycline in outpatient treatment of pelvic inflammatory disease. South Med J 1993 Jun; 86: 604-10
157. Wendel Jr GD, Cox SM, Bawdon RE, et al. A randomized trial of ofloxacin versus cefoxitin and doxycycline in the outpatient treatment of acute salpingitis. Am J Obstet Gynecol 1991 May; 164: 1390-6
158. Bellina J, Toth M, Kahn JB, et al. A prospective, multicenter study to evaluate the safety and efficacy of ofloxacin in the treatment of laparoscopically documented acute salpingitis (PID) [abstract]. 36th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1996 Sep 15: 255
159. Soper DE, Brockwell NJ, Dalton HP. Microbial etiology of urban emergency department acute salpingitis: treatment with ofloxacin. Am J Obstet Gynecol 1992 Sep; 167: 653-60
160. Matsuda S, Oh K, Ando S, et al. Double-blind comparative study on grepafloxacin and ofloxacin in infectious diseases in the obstetric and gynecological field [in Japanese]. Jpn J Chemother 1997 Jul; 45: 525-52
161. Stephens A, Kivikoski A, Kunda K, et al. A randomized, double-blind comparison of oral ofloxacin to cefotetan and doxycycline for inpatient treatment of pelvic inflammatory disease [abstract]. 5th International Symposium on New Quinolones; 1994 Aug 25-7; Singapore, 161
162. Faro S, Martens MG, Maccato M, et al. Effectiveness of ofloxacin in the treatment of Chlamydia trachomatis and Neisseria gonorrhoeae cervical infection. Am J Obstet Gynecol 1991 May; 164 Suppl. 2: 1380-3
163. Møller BR, Herrmann B, Ibsen HHW, et al. Occurrence of Ureaplasma urealyticum and Mycoplasma hominis in non-gonococcal urethritis before and after treatment in a double-blind trial of ofloxacin versus erythromycin. Scand J Infect Dis 1990; 22 Suppl. 68: 31-4
164. Perea EJ, Aznar J, Herrera A, et al. Clinical efficacy of new quinolones for therapy of nongonococcal urethritis. Sex Transm Dis 1989 Jan-March; 16 (1): 7-10
165. Taylor-Robinson D. Ureaplasma urealyticum (T-strain mycoplasma) and Mycoplasma hominis. In: Mandell GL, Bennett JE, Dolin R, editors. Principles and practice of infectious diseases, 4th ed. v. 2. New York: Churchill Livingstone, 1995: 1713-8
166. Lo KK, Lai CF, Tang KC, et al. Clinical evaluation of ofloxacin in male urethritis in Hong Kong [extended abstract]. Drugs 1993; 45 Suppl. 3: 372-3
167. Ziegler C, Stary A, Mailer H. et al. Quinolones as an alternative treatment of chlamydial, mycoplasma and gonococcal urogenital infections. Dermatology 1992: 185 (2): 128-31
168. Ballard RC, Radebe F, Mampuru M, et al. A comparison of ofloxacin and ciprofloxacin in the treatment of chancroid [abstract]. Sex Transm Dis 1994 Mar-Apr; 21 Suppl.: S135
169. Sanders, Jr WE. Oral ofloxacin: a critical review of the new drug application. Clin Infect Dis 1992; 14: 539-54
170. Blomer R, Bruch K, Krauss H et al. Safety of ofloxacin: adverse drug reactions reported during phase-II studies in Europe and Japan. Infection 1986; 14 Suppl. 4: S332-4
171. Jüngst G, Mohr R. Side effects of ofloxacin in clinical trials and in postmarketing surveillance. Drugs 1987; 34 Suppl. 1: 144-9
172. Hanafusa T, Sawada M, Shimizu K, et al. Overview of post-marketing surveillance of ofloxacin in Japan. Drugs 1993; 45 Suppl. 3: 441-2
173. Li JT, Yoshida M, Nakatsuka K. Phase IV study (postmarketing surveillance) of Tarivid (ofloxacin) in China. Drugs 1995; 49 Suppl. 2: 474-6
174. Sawada M, Nakamura S, Yamada A, et al. Phase IV study and post-marketing surveillance of ofloxacin in Japan. Chemotherapy 1991; 37: 134-42
175. Daiichi Pharmaceutical Co. Ltd. Tarivid® tablets (Ofloxacin) 100mg prescribing information, Tokyo, Japan. September 1996
176. Ball P, Tillotson G. Tolerability of fluoroquinolone antibiotics. Drug Saf 1995; 13 (6): 343-58
177. Rubinstein E, Potgieter P, Davey P. et al. The use of fluoroquinolones in neutropenic patients - analysis of adverse effects. J Antimicrob Chemother 1994 Jul: 34: 7-19
178. Jüngst G, Mohr R. Overview of postmarketing experience with ofloxacin in Germany. J Antimicrob Chemother 1988; 22 Suppl. C: 167-75
179. Pierfitte C, Royer RJ. Tendon disorders associated with fluoroquinolones [abstract]. Therapie 1995; 50 Suppl: 136
180. Moore ND, Breemeersch C, Noblet C. Renal failure with fluoroquinolones: a national investigation by the French pharmacovigilance system [abstract]. Pharmacoepidemiol Drug Saf 1996 Aug; 5 Suppl. 1: S61
181. Sörgel F, Kinzig M. Pharmacokinetics of gyrase inhibitors. Part 2: renal and hepatic elimination pathways and drug interactions. Am J Med 1993; 94 Suppl. 3A: 56S-69S
182. Davies BI, Maesen FPV. Drug interactions with quinolones. Rev Infect Dis 1989 Jul-Aug; 11 Suppl. 5: S1083-90
183. Depperman K-M, Lode H. Fluoroquinolones: interaction protile during enteral absorption. Drugs 1993; 45 Suppl. 3: 65-72
184. Tack KJ, Smith JA. The safety profile of ofloxacin. Am J Med 1989 Suppl. 6C: 78S-81S
185. Parent M, LeBel M. Meta-analysis of quinolone-theophylline interactions. DICP 1991; 25: 191-4
186. Katagiri Y, Naora K, Ichikawa N, et al. Absence of pharmacokinetic interaction between ofloxacin and fenbufen in rats. J Pharm Pharmacol 1989; 41: 717-9
187. Fillastre JP, Leroy A, Borsa-Lebas F, et al. Lack of effect of keloprofen on the pharmacokinetics of pelloxacin and ofloxacin. J Antimicrob Chemother 1993 May; 31: 805-6
188. Jüngst G, Weidmann F., Breitstadt A, et al. Does ofloxacin interact with nonsteroidal anti-inflammatory drugs to cause psychotic side effects. 17th International Congress of Chemotherapy. 1991 Jun 23-8; Berlin.
189. Takahashi J, Kawakatsu K, Sawaoka H, et al. Effect of metal ions on bioavailability of ofloxacin [in Japanese]. Igaku Yakugaku 1995; 34 (1): 59-64
190. Albrecht D, Zahorsky R, Krausse R, et al. Influence of magnesium-and aluminium hydroxide on pharmacokinetic data of ofloxacin in patients with a prophylaxis of peptic ulcer [abstract]. Naunyn Schmiedebergs Arch Pharmacol 1992; 345 Suppl.: R1
191. Sánchez-Navarro A, Martínex-Cabarga M, Dominguez-Gil Hurlé A. Oral absorption of ofloxacin administered together with aluminum. Antimicrob Agents Chemother 1994 Oct; 38: 2510-2
192. 2+ on absorption parameters of ciprofloxacin and ofloxacin. J Antimicron Chemother 1994 Jul; 34: 119-25
193. Lehto P, Kivistö KT. Effect of sucralfate on absorption of norfloxacin and ofloxacin. Antimicrob Agents Chemother 1994 Feb; 38: 248-51
194. Martinez-Cabarga M, Sánchez-Navarro A, Colino-Gandarillas CI, et al. Effects of two cations on gastrointestinal absorption of ofloxacin. Antimicrob Agents Chemother 1991 Oct; 35: 2102-5
195. Verho M, Malerczyk V, Rosenkranz, B, et al. Absence of interaction between ofloxacin and phenprocoumon. Curr Med Res Opin 1987; 10: 474-9
196. Nakanishi S, Okuno H. Comparison of inhibitory effects of new quinolones on drug metabolizing activity in the liver. Jpn J Pharmacol 1990 May; 53: 81-96
197. Martin DE, Shen J, Griener J, et al. Effects of ofloxacin on the pharmacokinetics and pharmacodynamics of procainamide. J Clin Pharmacol 1996 Jan; 36: 85-91
198. Foote EF, Halstenson CE. Effects of probenecid and cimetidine on renal disposition of ofloxacin in rats. Antimicrob Agents Chemother 1998 Feb; 42: 456-8
199. Brown NM, White LO, Blundell EL, et al. Absorption of oral ofloxacin after cytotoxic chemotherapy for haematological malignancy. J Antimicrob Chemother 1993 Jul; 32: 117-22
200. Paintaud G, Alván G, Hellgren U, et al. Lack of effect of amoxycillin on the absorption of ofloxacin. Eur J Clin Pharmacol 1993; 44 (2): 207-9
201. Weber P, Boussougant Y, Farinotti R, et al. Serum bactericidal activity against Enterobacteriaceae producing broad-spectrum beta-lactamases in volunteers administered ofloxacin and cefotaxime, alone or combined. Eur J Clin Microbiol Infect Dis 1989; 8: 524-6
202. Boeckh M, Grineisen S, Shokry F, et al. Pharmacokinetics and serum bactericidal activity of cirofloxacin and ofloxacin alone and in combination with metronidazole or clindamycin [abstract no. 770]. 28th Interscience Conference on Antimicrobial Agents and Chemotherapy, 1988 Oct 23-26; LA (CA)
203. Vogt P, Schorn T, Frei U. Ofloxacin in the treatment of urinary tract infection in renal transplant recipients. Infection 1988 May-Jun; 16: 175-8
204. Hölfken G, Lode H, Borner K, et al. Interactions in the kinetics of ofloxacin. In: Marget et al., editors. Bacterial infections, antibacterial chemotherapy, 1986: 144-5. MMV Medizin Verlag; Munich, Germany
205. Anonymous. Mosby's complete drug reference. Physician's Generix. 7th ed. St Louis: Mosby, 1997
206. Anonymous. ABPI Compendium of data sheets. London: Datapharm Publications Limited, 1996-7
207. Daiichi Pharmaceutical Co. Ltd. Tarivid® tablets (Ofloxacin) 100mg prescribing information, Tokyo, Japan, September 1996
208. Berg AO, Handsfield HH, Holmes KK, et al. 1993 sexually transmitted diseases treatment guidelines. MMWR 1993 Sep 24; 42 (No. RR-14): 1-102
209. Ortho Floxin is first oral monotherapy for pelvic inflammatory disease; cost and lack of anaerobic coverage may be key acceptance issues. Pharm Approv Mon 1997 Feb; 2: 22-4
210. Rice PA, Schachter J. Pathogenesis of pelvic inflammalory disease: what are thee questions? JAMA 1991 Nov 13; 266 (18): 2587-93
211. Nathwani D, Tillotson G, Davey P. Sequential antimicrobial therapy: the role of quinolones. J Antimicrob Chemother 1997; 39: 441-6
212. Krop CL. Ofloxacin: why the increased popularity? J Pharm Technol 1996 May-Jun; 12: 88-96